- Home
- ADSE vs TBPH Comparison
ADSE vs TBPH Comparison
Compare ADSE & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADSE | TBPH |
|---|---|---|
| Founded | 1980 | 2013 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 900.0M | 908.9M |
| IPO Year | 2021 | 2013 |
Fundamental Metrics
Financial Performance| Metric | ADSE | TBPH |
|---|---|---|
| Price | $11.18 | $17.09 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $18.40 |
| AVG Volume (30 Days) | 15.8K | ★ 402.8K |
| Earning Date | 05-01-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 279.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $15,386,000.00 |
| Revenue This Year | $549.86 | $8.46 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.89 | $13.08 |
| 52 Week High | $13.50 | $21.03 |
Technical Indicators
Market Signals| Indicator | ADSE | TBPH |
|---|---|---|
| Relative Strength Index (RSI) | 41.58 | 65.63 |
| Support Level | $10.98 | $16.80 |
| Resistance Level | $12.02 | $17.11 |
| Average True Range (ATR) | 0.39 | 0.05 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 28.57 | 91.89 |
Price Performance
Historical ComparisonAbout ADSE ADS-TEC ENERGY PLC
ADS-TEC Energy PLC produces, develops, and markets battery-buffered EV charging systems infrastructure, battery storage systems, and cloud-based services that enable the customer to control and manage the system. The company generates revenue mainly through the sale of its products, services, and Big-LinX. Geographically, it derives a majority of its revenue from Germany.
About TBPH Theravance Biopharma Inc.
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.